http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114191540-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a61b3ac124a5f1c4a12a7ae78527465 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2021-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7035a004b9d3053358a7755f33bc654 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf688851177474cc056b72e51b0bd825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_196834a9706ebcde261ff960cbc314d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b7bbde02087752e85e5744d403ead39 |
| publicationDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114191540-A |
| titleOfInvention | Use of CTRP13 in the preparation of drugs for preventing and treating vascular and tumor diseases |
| abstract | The invention belongs to the research in the application field of CTRP13, and particularly relates to the use of CTRP13 in the preparation of medicines for preventing and treating vascular and tumor diseases. Mainly disclosed: the application of CTRP13 in the preparation of angiogenesis-inhibiting drugs. In this application, the application is the application of CTRP13 in the preparation of anti-tumor angiogenesis drugs. Application of CTRP13 in the preparation of preparations for inhibiting activation of angiogenesis signal transduction pathway. Application of CTRP13 in the preparation of preparations for inhibiting VEGFR2 molecular signaling pathway. Application of CTRP13 in the preparation of drugs for promoting HUVEC cell proliferation and/or HUVEC cell migration. In this application, in some ways, the CTRP13 is a CTRP13 protein or a CTRP13 gene overexpression molecule. Application of CTRP13 in the preparation of drugs for preventing and treating subretinal angiogenesis diseases. In the present invention, CTRP13 has an inhibitory effect on the VEGFR2 signaling pathway, and CTRP13 can become a new target for anti-tumor angiogenesis, thereby preventing or treating the occurrence and development of tumors; CTRP13 can also be used as a treatment for endothelial cells involved in retinal angiogenesis, vascular injury, etc. medicines for diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114533853-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114533853-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113559244-A |
| priorityDate | 2021-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 91.